Functionalized nanospheres for targeted delivery of paclitaxel  by Bushman, Jared et al.
Journal of Controlled Release 171 (2013) 315–321
Contents lists available at ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre lFunctionalized nanospheres for targeted delivery of paclitaxel
Jared Bushman, Asa Vaughan, Larisa Sheihet, Zheng Zhang, Marius Costache, Joachim Kohn ⁎
New Jersey Center for Biomaterials and Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, 145 Bevier Road, Piscataway, NJ 08854, USAAbbreviations: αCD44, anti-CD44 antibody; bTyr-NS
nanospheres; bTyr-NSP-PTX, biotinylated tyrosine-derived
taxel; CTAB, cetyltrimethylammoniumbromide; ESA, epith
dicyclohexylcarbodiimide; DMF, dimethylformamide;
DPTs, 4-dimethylaminopyridinium-p-toluene sulfate; DTO
ester; EPR, enhanced permeability and retention; GPC, ge
HOBT, hydroxybenzotriazole; Kd, dissociation constant
NMR, nuclear magnetic resonance; Oligo(DTO-SA), oligom
octyl ester and suberic acid; PBS, phosphate buffered sali
PTX, paclitaxel; SA, suberic acid; StA, streptavidin; T
tyrosine-derived nanospheres; Tyr-NSP-PTX, tyrosine de
paclitaxel.
⁎ Corresponding author. Tel.: +1 732 445 3888; fax:
E-mail address: kohn@rutgers.edu (J. Kohn).
0168-3659 © 2013 The Authors. Published by Elsevier B
http://dx.doi.org/10.1016/j.jconrel.2013.06.017a b s t r a c ta r t i c l e i n f oArticle history:
Received 8 March 2013
Accepted 10 June 2013
Available online 20 June 2013
Keywords:
Nanosphere
Paclitaxel
Targeting
Biotinylation
Breast cancer
Pretargeted radioimmunotherapyTargeted delivery of anti-cancer agents to cancer cells is a mature line of investigation that has yet to realize
its full potential. In this study we report on the development of a delivery platform with the future goal of
merging two thus far parallel methods for selective elimination of cancer cells: targeted nanospheres
and pretargeted radioimmunotherapy. Several clinical trials have shown the promise of pretargeted
radioimmunotherapy, which leverages the speciﬁcity of antibodies for targeted cell populations and delivers
a localized dose of a biotinylated radionuclide that is most often administered following binding of a
biotinylated antibody and streptavidin (StA) to the target cells. The work presented here describes the devel-
opment of biotinylated nanospheres based on an ABA-type copolymer comprised of a tyrosine-derived olig-
omer as the B-block and poly(ethylene glycol) (PEG) A-blocks. The biotinylated nanospheres encapsulate
paclitaxel (PTX) to the same extent as unbiotinylated nanospheres. Efﬁcacy of targeting was shown on
CD44 positive cells in the SUM159 breast cancer cell line by incubating the cells sequentially with a
biotinylated anti-CD44 antibody, StA and the biotinylated nanospheres encapsulating PTX. Targeted
nanospheres achieved the half maximal inhibitory concentration of PTX on SUM159 cells at a 5–10 fold
lower concentration than that of PTX applied in either non-targeted nanospheres or free drug approaches.
Moreover, targeted nanospheres selectively eliminated CD44 positive SUM159 cells compared to free PTX
and untargeted nanospheres. This new generation of nano-sized carrier offers a versatile platform that can
be adopted for a wide variety of drug and target speciﬁc applications and has the potential to be combined
with the clinically emerging method of pretargeted radioimmunotherapy.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.1. Introduction
Drug delivery via nanoparticle-based carriers has shown promis-
ing pharmacological results for cancer therapy. Paclitaxel-(PTX)
containing nanoparticles have been approved by the FDA for breast
cancer treatment (Abraxane®) and several nanoparticulate formula-
tions containing various chemotherapy drugs, such as PTX, doxorubi-
cin (DOX), and cisplatin are currently in clinical trials [1,2]. AmongP, biotinylated tyrosine-derived
nanospheres loaded with pacli-
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l permeation chromatography;
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rived nanospheres loaded with
+1 732 445 5006.
.V. Open access under CC BY-NC-SA licthe biomaterials applied as the matrix of nano-sized drug carriers,
focus has been given to copolymers where both chemical composi-
tion and supramolecular structure can be adjusted to meet speciﬁc
criteria. Amphiphilic block copolymers have particular promise
since they self-assemble in aqueous environment and form a core–
shell structure, enabling the encapsulation of the lipophilic drugs,
prolonged circulation time, and protection against uptake by the re-
ticuloendothelial system [3–7].
A strategy to further improve the therapeutic efﬁcacy of drug-
containing nanoparticles is to functionalize themwith targeting ligands
that have afﬁnities for speciﬁc types of cells or tissues. Successful
targeting will result in a speciﬁc concentration of the drug-containing
carriers at the intended site of delivery in a more precise manner as
compared to the passive accumulation of the nanocarriers due to the
enhanced permeability and retention (EPR) effect [8]. Targeted delivery
is hypothesized to help overcome aspects of drug resistance in chemo-
therapy [9]. Targeting typically involves covalent binding of a ligand to
the nanocarrier [10], and several recent examples of ligands are lectin to
target intestinal M-cells [11], A10 aptamer for prostate cancer cells [12],
folic acid to target ovarian A2780 cells [13] and Hela cells [14], and RGD
for metastatic cancer cells [15].
An additional method of cancer targeting is through pretargeted
radioimmunotherapy. Pretargeted radioimmunotherapy is a versatile
targeting method, where antibodies against cancer cells are used asense.
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such antibodies are either directly conjugated with streptavidin (StA)
(or other biotin-binding proteins) or biotinylated so that subsequent-
ly injected StA will bind to the biotinylated antibody. As StA has four
distinct and cooperative binding sites for biotin [17], it serves as the
docking platform to bind radiolabeled biotin that then accumulates
on the targeted cell. Several promising clinical trials have shown the
safety and efﬁcacy of this targeting method [18–25].
We have set out to develop a drug-delivery platform that lever-
ages the advancements in pretargeted radioimmunotherapy and
could be used instead of or in combination with radiolabeled biotin.
The basis of the platform is tyrosine-derived nanospheres (Tyr-NSP)
composed of block copolymers of desaminotyrosyl tyrosine octyl
ester and suberic acid oligomer (oligo(DTO-SA)) and PEG [26]. Previ-
ous reports documenting the Tyr-NSP showed encapsulation of hy-
drophobic molecules such as vitamin D3 [27], PTX [28–30] and a
variety of ﬂuorescent dyes [29]. Tyr-NSP displayed negligible toxicity
in vitro [26] and in vivo [31]. Biotinylation of Tyr-NSP was accom-
plished through the attachment of a heterobifunctional PEG to the
oligo(DTO-SA), which introduced free carboxylic acid end groups to
the polymer chain, providing a platform for the attachment of the bi-
otin targeting moiety. Biotinylated Tyr-NSP (bTyr-NSP) were capable
of binding StA, encapsulating PTX and showed improved efﬁcacy at
killing CD44 positive SUM159 cancer cells in vitro when combined
with a biotinylated anti-CD44 antibody and StA modeled after what
is employed with pretargeted radioimmunotherapy.
2. Materials and methods
2.1. Materials
Methylene chloride (HPLC grade), acetic acid, N,N-dimethyl-
formamide (DMF), tetrahydrofuran (THF), 2-propanol and Ez-Link
Amine-PEG2-Biotin (MW = 374.5) were purchased from Fisher Scientif-
ic (Pittsburgh, PA). Suberic acid (SA), cetyltrimethylammonium bromide
(CTAB), N,N′-dicyclohexylcarbodiimide (DCC), hydroxybenzotriazole
(HOBT), and phosphate buffered saline (PBS) were purchased from Al-
drich Chemical Co. (Milwaukee, WI). N-hydroxysuccinimide (NHS) was
purchased fromAcros Organics (Geel, Belgium). Diisopropylcarbodiimide
(DIPC) was purchased from Tanabe Chemicals (San Diego, CA). The het-
erobifunctional PEG, NH2–PEG–COOH (5000 Da from the product speciﬁ-
cation; weight averagemolecular weightMw = 4.0 kDa asmeasured by
GPC) was purchased from Laysan Bio (Arab, AL). Desaminotyrosyl-
tyrosine octyl ester (DTO), 4-dimethylaminopyridinium-p-toluene
sulfate (DPTs) and DTO-SA/PEG5K (Mw = ~27 kDa) were synthesized
using published procedures [29]. All chemicals were used as received.
2.2. Analytical techniques and used instrumentation
1H NMR spectra were recorded on a Varian VNMRS 500 MHz
(Agilent, Santa Clara, CA) at 25 °C. 1H NMR spectra were calibrated to
the solvent signal of DMSO-d6 (δ = 2.50 ppm). Chemical shifts were
provided in ppm. The following abbreviations for the peak multiplicities
were used: s, singlet; d, doublet; dd, double doublet; t, triplet; q, quadru-
plet;m,multiplet; br, broad. GPC systemconsisted of a 515HPLC pump, a
717 plus autosampler, 410 RI detector, and Empower 2 software (Waters
Corporation). Two PL gel columns 103 and 105 Å (Polymer Laboratories/
Agilent, Santa Clara, CA) were used in series with THF as the mobile
phase at a ﬂow rate of 1 mL/min. The system was calibrated with poly-
styrene standards (Polymer Laboratories/Agilent, Santa Clara, CA).
2.3. Synthesis of the triblock copolymer
The triblock copolymer, HOOC–PEG–oligo(DTO-SA)–PEG–COOH,
was synthesized in a three step reaction process: synthesis of the hy-
drophobic core oligo(DTO-SA), NHS esteriﬁcation of the carboxylic acidend groups, followed by the attachment of the heterobifunctional PEG
(NH2–PEG–COOH).2.3.1. Synthesis of oligo(DTO-SA)
Oligo(DTO-SA) was prepared by a DIPC and DPTs-catalyzed reac-
tion of DTO and SA. The reaction was quenched with CTAB and
water. The oligomer was puriﬁed and the molecular weight (Mw =
22 kDa and Mn = 15 kDa, by GPC) and the 1H-NMR spectrum of
the compound obtained were found to be identical to oligo(DTO-SA)
as previously described [28].2.3.2. NHS esteriﬁcation of oligo(DTO-SA) (Fig. 1, Product 1)
500 mg (3.33 × 10−5 mol) of oligo(DTO-SA), 10.5 mg (9.12 ×
10−5 mol) of NHS, and 3 mL of methylene chloride were combined
in a 25 mL round-bottom ﬂask. With continuous stirring at room tem-
perature, 16 μL of DIPCwas added to themixture. After 2 h, the reaction
was quenched by the addition of 9 μL of acetic acid and allowed to stir
for 20 min. Product 1 was isolated by precipitation in 2-isopropanol
and puriﬁed as described before [28].2.3.3. Attachment of heterobifunctional PEG (Fig. 1, Product 2)
We added the following into a 25 mL round bottomed ﬂask:
102.5 mg (4.77 × 10−5 mol) of Product 1, 1 mL of methylene chloride,
and 60.1 mg (1.43 × 10−4 mol, 3 equivalents to Product 1) of NH2–
PEG–COOH. Themixture was allowed to stir at room temperature over-
night. The PEGylated triblock copolymer (Product 2) was isolated and
puriﬁed as described [28], characterized by GPC (Mw = 30 kDa and
Mn = 22 kDa), and 1H NMR (DMSO-d6, 500 MHz): 8.34 ppm (d, NH),
7.78 ppm (m, polymer-CO-NH-PEG-COOH), 7.19–6.94 ppm (m, Ar–H),
4.45 ppm (d, CH of DTO), 3.93 ppm (m, of the octyl pendant chain in
the DTO), 3.50 ppm (dd, CH2CH2 of PEG), 3.35 ppm (m, OCH3 of PEG),
2.95–2.85 (m, CH2 of DTO), 2.71 (m, CH2 of SA), 2.48 (m, CH2 of SA),
2.35 (m, CH2 of DTO);1.63 (p, CH2 of SA), 1.44 (p, CH2 of the octyl pen-
dant chain in the DTO) 1.37 (p, CH2 of SA), 1.20 (m, CH2 of the octyl pen-
dant chain in the DTO), 0.83 (m, CH3 of the octyl pendant chain in the
DTO). Addition of the heterobifunctional PEG was 100% efﬁcient relative
to oligo(DTO-SA).2.4. Biotinylation of the triblock copolymer (Fig. 1, Product 3)
Synthesis of biotin–PEG–oligo(DTO-SA)–PEG–biotin (Product 3)
was carried out as follows: 380 mg (1.36 × 10−5 mol) of Product 2,
9.2 mg (6.78 × 10−5 mol, 5 equivalents to the polymer) of HOBT,
and 1.5 mL of DMF were combined in scintillation vial. With continu-
ous stirring at room temperature, 14.1 mg (6.78 × 10−5 mol, 5
equivalents to the polymer) of DCC was added to the mixture and
the reaction was allowed to stir for 30 min. To this mixture,
15.2 mg (4.07 × 10−5 mol, 3 equivalents to the polymer) of EZ link
Amine-PEG2-Biotin was added. The mixture was allowed to stir over-
night and reaction was quenched by the addition of 6.1 μL of acetic
acid. The biotin-functionalized polymer was isolated and puriﬁed as
described above (Section 2.3.1). Product 3 was characterized by
GPC (Mw = 30 kDa and Mn = 22 kDa) and 1H NMR (DMSO-d6,
500 MHz): 8.34 ppm (d, NH), 7.19–6.94 ppm (m, Ar–H), 6.45–
6.32 ppm (m, CH in tetrahydroimidizalone ring in biotin), 4.44 ppm
(d, CH of DTO), 3.95 ppm (m, OCH2 of the octyl pendant chain in
the DTO), 3.51 ppm (dd, CH2CH2 of PEG), 3.35 ppm (m, OCH3 of
PEG), 2.95–2.84 (m, CH2 of DTO), 2.73 (m, CH2 of SA), 2.53 (m, CH2
of SA), 2.37 (m, CH2 of DTO); 1.63 (p, CH2 of SA), 1.44 (p, CH2 of the
octyl pendant chain in the DTO) 1.37 (p, CH2 of SA), 1.20 (m, CH2 of
the octyl pendant chain in the DTO), 0.82 (m, CH3 of the octyl pendant
chain in the DTO). Based on the integration of NMR peaks, 89% of the
carboxylic acid groups on Product 2 were biotinylated.
Fig. 1. Synthesis of biotinylated tyrosine-derived triblock copolymer. Reagents and con-
ditions: (a) NH2–PEG–COOH, 20 °C, CH2Cl2. (b) DCC, HOBT, EZ Amine-PEG2-Biotin,
DMF.
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Self-assembly of the biotinylated polymers into nanospheres
(bTyr-NSP) was induced by drop-wise addition of 150 mg/mL of
Product 3 and non-biotinylated DTO-SA/PEG5K (1:3 w/w) in DMF so-
lution into 0.1 M PBS (pH 7.4) under mild agitation. Preparation and
characterization of Tyr-NSP and bTyr-NSP were carried out as previ-
ously reported [29].
2.6. Veriﬁcation of biotin accessibility
To conﬁrm the accessibility of the biotin-targeting moiety on
bTyr-NSP in aqueous suspension, 300 μL of bTyr-NSP or Tyr-NSP sus-
pensions (polymer content approximately 10 mg/mL) were incubat-
ed for 30 min at room temperature with 200 μL PBS solution
containing 0, 10, 50 and 100 μg of FITC-conjugated Streptavidin
(FITC-StA, Invitrogen, Carlsbad, CA). The mixtures were centrifuged
at 65,000 rpm for 3 h and the pelleted bTyr-NSP and Tyr-NSP were
re-dispersed in PBS. The ﬂuorescence intensity (excitation/emission
wavelengths at 488 nm/519 nm) was recorded with Tecan Inﬁnite
M200 PRO microplate reader. PBS was used as internal standard and
the relative ﬂuorescence intensity was reported as the ratio between
the ﬂuorescence intensity of the test sample and that of PBS. 4 inde-
pendent experiments were performed.
2.7. Paclitaxel-loaded nanospheres
Preparation and characterization of paclitaxel-loaded tyrosine-
derived nanospheres (Tyr-NSP-PTX) and paclitaxel-loaded biotinylated-
tyrosine-derived nanospheres (bTyr-NSP-PTX) were performed ac-
cording to previously established procedure [32] with the following
modiﬁcation: the feed ratio between the PTX and triblock copolymer
changed to 1% w/w. The binding and loading efﬁciencies of PTX by
bTyr-NSP and Tyr-NSP were determined using previously reported
extraction and HPLC techniques [30,32].
2.8. Cell culture
SUM159 human breast carcinoma cells were obtained courtesy of
Dr. Prabhas Moghe at Rutgers, The State University of New Jersey.
SUM159 cells were cultured in media consisting of Ham's F12
(Invitrogen, Carlsbad, CA), 5 μg/mL bovine pancreas insulin (Sigma
Aldrich, Milwaukee, WI), 1 μg/mL hydrocortisone, 10 mM HEPES
(Lonza, Allendale, NJ), 1× Penicillin:streptomycin (Fisher Scientiﬁc,
Pittsburgh, PA), and 5% fetal bovine serum, FBS (Atlanta Biologicals,
Lawrenceville, GA). Cells were maintained at sub-conﬂuent levels
with media changes every 2–3 days.2.9. Cell targeting and immunocytochemistry
SUM159 cells were plated at a density of 5000 cells per well onto
12 mm glass cover slips in a 24-well plate and incubated overnight.
Biotinylated anti-CD44 (eBioscience, San Diego, CA) antibody was
added to cells at manufacturers recommended dilution (1:50 v/v) in
the media without FBS and incubated on cells for 30 min followed
by media removal. StA was then added to the wells at a 5-fold
molar excess of the antibody concentration and incubated for another
30 min. Cells were gently washed twice with pre-warmed Dulbecco's
phosphate buffered saline (dPBS) and PTX-containing biotinylated
nanospheres (bTyr-NSP-PTX) were added in with FBS containing
media. Various conditions were tested with cultures treated identi-
cally but substituting the control treatments for bTyr-NSP-PTX. Fol-
lowing addition of treatments, cells were cultured for an additional
72 h at which point the cells were gently washed with pre-warmed
dPBS and ﬁxed with 2% paraformaldehyde for 15 min. Cover slips
were blocked with a solution containing 20% donor calf serum and
then immuno-stained for CD44 (1:100 dilution) followed by an
Alexa Fluor®-488 secondary antibody (Invitrogen, Carlsbad, CA),
stained with a Hoechst and ﬂuorescent microscopy was used to
count and determine the number of surviving CD44 positive and
CD44 negative cells that did not show DNA fragmentation character-
istic of PTX induced cell death [33].
2.10. Cell viability assays
SUM159 cells were plated at a density of 3000 cells per well into
96-well plates and allowed to adhere overnight. The following day,
cells were targeted as described above and allowed to culture for
72 h. Cells were gently washed twice with pre-warmed dPBS and
then media containing 10% v/v AlamarBlue® reagent (Fisher) were
placed into the wells and absorbance readings were taken to deter-
mine reduction of resazurin into resoruﬁn. Wells given bTyr-NSP
without cells and washed twice with the pre-warmed dPBS showed
that there was no effect of the nanospheres on AlamarBlue®. At
least 3 independent experiments were performed and results were
% normalized to the control of no PTX and are presented as a mean
value with its standard error indicated (mean ± SEM).
2.11. Statistics
All data are the result of at least 3 independent experiments and
are presented as mean ± SEM. The Student's t-test was used to deter-
mine statistical signiﬁcance with * denoting p b 0.05, ** p b 0.005,
and *** p b 0.0005.
3. Results
3.1. Synthesis
The rationale for the synthetic route outlined in Fig. 1 was to pro-
duce tyrosine-derived triblock copolymer with free carboxylic acid
groups on the end of the hydrophilic PEG blocks. Provided that the
targeting ligand has an available reactive amine group, the covalent
attachment of a wide variety of functional moieties to this polymer
can be achieved via amide bond formation.
With the successful synthesis of HOOC–oligo(DTO-SA)–COOH ac-
cording to published procedures [28], heterobifunctional PEG was
then conjugated in two separate steps. First, the carboxylic acid
ends of the oligomer were activated using NHS (Product 1). In the
second step, amide bonds were formed between the oligo(DTO-SA)
block and the amine-terminated heterobifunctional PEG (Product
2). This two-step procedure ensured that Product 2, the amphiphilic
triblock copolymer, had reactive carboxylic acid end groups. GPC
analysis of Product 2 showed an increase of 8 kDa in Mw (Mw of
Fig. 2. Relative ﬂuorescence (excitation/emission at 488 nm/519 nm) of bTyr-NSP and
Tyr-NSP suspensions after incubation with 0, 10, 50 and 100 μg of StA-FITC for 30 min,
ultra-centrifugation, and re-suspension. The ﬂuorescent intensity of PBS was used as
reference, e.g., the ratio between the ﬂuorescent intensity of the samples to that of
PBS was plotted (*p b 0.05 by Student's t-test, n = 4).
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which is in agreement with the attachment of 2 blocks of NH2–
PEG–COOH (Mw 4 kDa) to both sides of the oligomer. The PEGylation
was further conﬁrmed by 1H NMR analysis.
Product 2 with two PEG–COOH segments at the termini now con-
tains reactive groups that enable attachment of a wide variety of
molecules via the formation of a new amide bond. To verify this pos-
sibility and attach additional groups to Product 2, we utilized a com-
mercially available biotinylation reagent containing a short spacer
and a primary amine (EZ-Link Amine-PEG2-Biotin). This molecule
was attached to Product 2 using DCC as coupling agent to yield Prod-
uct 3, as conﬁrmed by 1H NMR. This validated the proposed synthetic
route.
3.2. Formation of bTyr-NSP and Tyr-NSP
To determine whether this modiﬁcation of the PEG end blocks af-
fected self-assembly into nanospheres, Product 3 was mixed with
non-biotinylated DTO-SA/5 K at a 1:3 w/w ratio in DMF, and added
to PBS to form nanospheres using established procedures [26,28,32].
Hydrodynamic diameters of resulting bTyr-NSP and control Tyr-NSP
were 64.1 ± 0.5 and 63.8 ± 1.2 nm, respectively, indicating that
the presence of the biotin moiety did not signiﬁcantly affect the as-
sembly and size distribution of the nanospheres.
The incorporation of biotin was designed to act as a means to teth-
er a variety of functional moieties onto bTyr-NSP via the biotin–StA
interaction. StA contains four discreet biotin-binding sites and binds
biotin at exceptionally high afﬁnity in a cooperative fashion [17]. As
biotin is relatively hydrophobic, the accessibility of biotin molecules
on the surface of the nanospheres is a key issue. To assess this ques-
tion, bTyr-NSP and Tyr-NSP were separately incubated with ﬂuores-
cently labeled StA (StA-FITC). Following 30 min of incubation, the
bTyr-NSP/FITC-StA and Tyr-NSP/FITC-StA were centrifuged and the
unbound StA-FITC in the supernatant was removed. The ﬂuorescence
intensity of the re-suspended bTyr-NSP and Tyr-NSP was measured
and compared with that of PBS as a control. The relative ﬂuorescence
intensity values compared to PBS were plotted against the applied
StA-FITC amount (Fig. 2).
Without adding StA-FITC, both Tyr-NSP and bTyr-NSP showed no
difference as compared to PBS (relative ﬂuorescence intensity =
1.03 ± 0.03 and 1.05 ± 0.05, respectively). Tyr-NSP showed a slight
increase in the relative ﬂuorescence intensity with the applied
amount of StA-FITC (relative ﬂuorescence intensity values ranged be-
tween 1.4 and 3.9 when 10–100 μg of StA-FITC were applied), indi-
cating weak non-speciﬁc binding of StA-FITC onto the Tyr-NSP
surfaces. The binding of StA-FITC to bTyr-NSP was clearly illustrated
as the relative ﬂuorescence intensity values increased substantially
with the dose of StA-FITC (Fig. 2).
3.3. Loading of PTX into Tyr-NSP and bTyr-NSP
To investigate whether the addition of biotin affected the ability
of bTyr-NSP to encapsulate lipophilic drugs, PTX was loaded into
bTyr-NSP and control Tyr-NSP using procedures previously reported
[26–28,32]. Loading and binding efﬁciencies of PTX into Tyr-NSP
(Tyr-NSP-PTX) were 1.2 ± 0.2% and 45.0 ± 4.0% and for bTyr-NSP-PTX
1.2 ± 0.3% and 44.8 ± 6.5%, respectively. Thus, the measured binding
and loading efﬁciencies for the encapsulation of PTX into bTyr-NSP
were equivalent to the efﬁciencies obtained from the control Tyr-NSP
conﬁrming that the presence of the biotin moiety did not alter the drug
encapsulation ability of the nanospheres.
3.4. Cell speciﬁc targeting in vitro
The ability of bTyr-NSP-PTX to target speciﬁc cell sub-populations
was evaluated using SUM159 cells, a basal-type human primarybreast cancer cell line. SUM159 cells are tumorogenic in murine xeno-
graft studies and contain both CD44 positive and negative cells. While
both CD44 positive and negative cells initiate tumors in xenograft
studies, a CD44 positive sub-population of SUM159 cells show in-
creased malignancy and chemoresistance compared to CD44 negative
cells [34,35]. A targeting protocol was developed based on the
basic mechanism of biotin–StA interactions and consistent with
clinical protocols for pretargeted radioimmunotherapy [16]. In our
experimental setup, SUM159 cells were ﬁrst incubated with a
biotinylated anti-CD44 antibody then StA to create the pretargeting
complex, followed by bTyr-NSP-PTX (Fig. 3). Measurements of cell via-
bility after 72 h of treatment showed that bTyr-NSP-PTX coupled with
this targeting approach effectively decreased the dosage of PTX neces-
sary to eliminate 50% of the cell population (Fig. 4). The half maximal in-
hibitory concentration (IC50) of SUM159 cells targeted by anti-CD44 +
StA + bTyr-NSP-PTX occurred between 0.5 nM and 1 nM of PTX, com-
pared to IC50 values between 1 nMand10 nMmeasured for untargeted
bTyr-NSP-PTX and Tyr-NSP-PTX in various forms. Untargeted experi-
mental groups, such as StA + bTyr-NSP-PTX or anti-CD44 + StA +
Tyr-NSP-PTX, were less effective than the targeted approach. It is also
noteworthy that both bTyr-NSP-PTX and Tyr-NSP-PTX applied alone
were more effective at eliminating SUM159 cells than free PTX. Finally,
control experiments using equivalent amount of bTyr-NSP, but without
PTX, following anti-CD44 and StA showed no cytotoxicity.
To assess the CD44 immunoreactivity of the surviving cell types
after the 72 h treatment, SUM159 cells were subjected to varying
doses of PTX, using both targeted and non-targeted formulations,
and the immunoreactivity of the surviving cells was ascertained by
immunocytochemistry using a ﬂuorescent secondary antibody directed
against the anti-CD44 primary antibody. Cells undergoing PTX-induced
apoptosis showed a characteristic fragmenting of nucleic material,
making apoptotic and non-apoptotic cells easily distinguishable using
stains for DNA, such as Hoechst [33].
As shown in Fig. 5, the proportion of SUM159 cells without
fragmented DNA and positive for CD44 following treatments with
non-targeted bTyr-NSP-PTX or free PTX increased slightlywith elevated
doses of PTX. In contrast, when bTyr-NSP-PTX was targeted to CD44
positive cells using the biotinylated anti-CD44 antibody and StA, a selec-
tive decrease in the portion of cells without fragmented DNA that
stained positive for CD44 was observed. This effect increased
Fig. 3. Schematic representing the procedure used to target PTX-loaded bTyr-NSP
(bTyr-NSP-PTX) to CD44 positive SUM159 breast cancer cells. SUM159 cells were incu-
bated with a biotinylated anti-CD44 antibody, followed by streptavidin (StA), and then
bTyr-NSP loaded with PTX. The dimensions of the components do not correspond to
their actual relative sizes.
Fig. 4. Comparative toxicity of targeted and non-targeted PTX delivery on SUM159 cells
in vitro. bTyr-NSP-PTX was added to SUM159 cells following sequential incubation
with anti-CD44 (αCD44) and StA (StA) (αCD44 + StA + bTyr-NSP-PTX), or only StA
(StA + bTyr-NSP-PTX), or alone (bTyr-NSP-PTX). In comparison, Tyr-NSP-PTX was
added following sequential incubation with anti-CD44 and StA (αCD44 + StA +
Tyr-NSP-PTX), or alone (Tyr-NSP-PTX). Treatment control included bTyr-NSP without
PTX that followed incubation with anti-CD44 and StA. Free PTX group was diluted from
DMSO (0.1% v/v of DMSO in the ﬁnal cell culture media). All conditions were similarly
treated as the targeted αCD44 + StA + bTyr-NSP-PTX with respect to washes prior to
addition of PTX (*p b 0.05, ***p b 0.0005 by Student's t-test comparing targeted treat-
ment (αCD44 + StA + bTyr-NSP-PTX) against all other conditions unless otherwise in-
dicated, n = 4).
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to diverge from untargeted PTX conditions at a dose of 0.5 nM of PTX.
4. Discussion
These results suggest that the targeted delivery of PTX via bTyr-
NSP-PTX not only enhanced the drug efﬁcacy on killing SUM159 cells,
but also selectively eliminated the CD44 positive cell population. Viabil-
ity experiments (Fig. 4) conﬁrmed that at PTX doses at or exceeding
10 nM for any treatment, very few viable cells remained. In non-
targeted PTX treatments this correlates with an increase in the propor-
tion of viable cells that stained positive for CD44 (Fig. 5C), and is sup-
ported by previous reports that a subset of CD44 expressing cells
within the SUM159 cell population are resistant to PTX treatment
[34]. There is an increasing body of evidence showing that subsets
of cellswithin cancer cell populations are bothmore capable of generat-
ing tumors as well as resistant to chemotherapy [36]. These results
underscore thewider promise of nanoparticle-baseddelivery of chemo-
therapeutics to both preferentially target themostmalignant cellswith-
in the tumor as well as attenuate adverse side effects [37].
Selective elimination of CD44 positive cells using this targeting ap-
proach seems to be in line with this promise. In two of the experi-
mental replicates, no CD44 positive cells without fragmented nuclei
characteristic of PTX toxicity were observed at 25 nM and 50 nM of
targeted PTX treatment. By using additional biotinylated antibodies,
such as anti-epithelial-speciﬁc antigen (ESA), together with anti-
CD44, it is likely possible to provide additional docking sites for
bTyr-NSP-PTX on the most malignant cells within the SUM159 popu-
lation. This may further increase the local concentration of PTX
surrounding these cells and lower the effective dosage required to
eliminate them.
Results from untargeted control conditions suggest the speciﬁcity
of the targeted approach. Untargeted nanosphere formulations in-
cluding bTyr-NSP-PTX, StA + bTyr-NSP-PTX did not selectively elim-
inate CD44 positive cells and were comparative to free PTX in their
effects on the percentage of surviving SUM159 cells positive for
CD44 (Fig. 5C). Furthermore, the control group of targeted bTyr-NSP
that did not contain PTX, anti-CD44 + StA + bTyr-NSP, showed no
effects on overall viability or the proportion of cells positive for
CD44. This indicates that the step-wise targeting scheme did not
affect the cells in the absence of PTX.A previous report by Pulkkinen et al. [38] also found an improve-
ment in the ability to eliminate cells using a biotin-based targeting
method. In that study, biotinylated poly(lactic acid) (PLA)–PEG
nanospheres were enriched on the cellular surface of glioma cells via a
biotinylated transferrin molecule connected to the PTX-containing
PLA–PEG nanospheres using neutravidin as a linker. High expression
of the transferrin receptor on glioma cells relative to most normal
brain tissue is hypothesized to assist with enriching the PTX-
containing nanoparticles on tumors. The authors noted that a reduction
in glioma cell viabilitywas achieved in vitro through this targeting com-
pared to untargeted approaches, but did not show a correlation be-
tween selective toxicity toward cells expressing transferrin.
The use of the presently described synthetic route for bTyr-NSP and
the method of targeting have several layers of versatility. First, the
triblock copolymers of DTO-SA/PEG5K comprising the nanospheres can
bemodiﬁed to promote speciﬁc rates of drug release. This occurs either
through changing theMw of the hydrophobic or hydrophilic segments,
or through altering the composition of the side chain within the hydro-
phobic desaminotyrosyl tyrosine (Fig. 1). The current report utilizes
octyl-ester for the side chain, whereas substitutions of dodecyl-ester
or ethyl-ester greatly vary the drug loading and release kinetics [32].
Secondly, the synthetic procedure described here for the tethering
of biotin is likely to be efﬁcacious for other targeting moieties with re-
active primary amines, and may enable direct targeting independent
of our current approach utilizing StA as the linkage to a biotinylated
antibody. However, care must be taken to ensure that such moieties
do not disrupt critical nanospheres properties as the polymer is
modiﬁed prior to nanosphere formulation; such may be the case if
the current scheme was adapted to directly attach the ~150 kDa
anti-CD44 antibody to the Tyr-NSP. Alternate chemistries have been
reported that enable attachment of antibodies after formulation of
nanospheres [39] and nanoparticles are routinely tethered to anti-
bodies [40]. It is noteworthy that other groups have reported on the
direct targeting using nanoparticles with smaller targeting moieties
[10–15,41,42], including antibody fragments [43,44]. Clinical success
of directly targeted nanospheres is pending further optimization of
these technologies [45].
Fig. 5. Selective effect of targeted bTyr-NSP-PTX on CD44 positive SUM159 cells. A–B:
Images of SUM159 cells stained for CD44 and Hoechst following treatments delivering
0.1 nM PTX (A) and 5 nM (B) of PTX via targeted (αCD44 + StA + bTyr-NSP-PTX)
and non-targeted approaches after 72 h. At 0.1 nM PTX, no differences in the relative
abundance of viable CD44 positive cells were observed for any treatment condition,
whereas at 5 nM of PTX, cultures receiving targeted PTX showed a decrease in the pro-
portion of viable cells staining positive for CD44. C: Quantiﬁcation of viable CD44 pos-
itive cells (without fragmented nuclei) after 72 h of treatment with targeted and
non-targeted PTX (***p b 0.0005 by student's t-test comparing targeted treatment
(αCD44 + StA + bTyr-NSP-PTX) against all other conditions, n ≥ 3, scale = 50 μm).
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interaction as it relates to pretargeted radioimmunotherapy. Clinical
studies have shown the efﬁcacy of this method of co-localization
against a wide variety of cancers, both solid and diffuse [18–25].This is possible simply by changing the antibody used to target the
cells and is one of the beneﬁcial aspects of a multi-component system.
There are a growing number of antibodies approved for human use
[46] and, importantly, StA appears to be well tolerated in cancer pa-
tients treated with pretargeted radioimmunotherapy even when
injected multiple times over a period of months. A clearing agent is
used to remove unbound antibody–StA complexes from circulation
prior to administration of the biotin radionuclide and may play an im-
portant role in the speciﬁcity of accumulation [16]. The afﬁnity of bi-
otin for StA, with a dissociation constant (Kd) of 10−14 to 10−15 M
[17], is the strongest known non-covalent interaction and is orders
of magnitude greater than most antibody–antigen interactions,
which generally range between ~10−6 to 10−9 M [47,48]. By clearing
unbound targeting complex, consisting of the antibody with StA, this
means that the accumulation of the biotinylated anti-cancer compo-
nent will be governed by the energetics of the biotin–StA and lowers
the likelihood of accumulation the anti-cancer component in non-
targeted areas.
While experimentation reported here uses three-step targeting ap-
proach, it may be advantageous for future work, especially in animal
models, to move to a two-step approach e.g. using preassembled anti-
body–StA conjugates as the pretargeting complex. Such two-step ap-
proaches are widely used in pretargeted radioimmunotherapy [25].
Using the conjugate pretargeting complexwould cut down on the num-
ber of injections necessary to provide the treatment, while still beneﬁt-
ting from the high afﬁnity of the biotin–StA interaction to dock the drug
carrier biotinylated nanospheres and/or the radiolabeled biotin to the
pretargeting complex on the target cell.5. Conclusions
The ABA-type triblock copolymer consisting of a tyrosine-derived
hydrophobic core and PEG hydrophilic corona was modiﬁed with a
chemical procedure that enables the attachment of a wide variety of
functional moieties. The attachment of Amine-PEG2-Biotin was
presented in this work and biotin was applied as a model targeting
motif. The biotinylated nanospheres loaded with PTX were success-
fully prepared and targeted to CD44 positive SUM159 breast cancer
cells by sequentially exposing the cells to a biotinylated anti-CD44 an-
tibody, StA and ﬁnally the biotinylated nanospheres containing PTX.
This treatment showed a signiﬁcantly enhanced cytotoxicity toward
the SUM159 human breast carcinoma cells at the population level,
but also showed preferential elimination of CD44 positive SUM159
cells. In this manner, a lower dose of PTX can be used to eliminate
cancer cells and can increase the local concentration of PTX surround-
ing the most resistant CD44 positive cancer cells. This modiﬁcation
gives rise to a new generation of tyrosine-derived nanospheres as
nano-sized drug delivery system offering versatility with respect to
direct targeting, drug encapsulation, and compatibility with any of
the clinically used antibody-based cancer therapies.Acknowledgments
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